[Piperacillin: microbiological and clinical studies].
A microbiological and clinical study of the action of piperacillin is presented. The drug showed an excellent in vitro antibacterial action on gram positive and gram negative microorganisms. Its in vitro action on Ps. aeruginosa (70.8% of strains inhibited) was also extremely interesting, making it the second most effective of the antibiotics tested after polymyxin B and colistin, polypeptides unsuitable for clinical use. In vivo, the administration of piperacillin achieved a clinical and bacteriological cure in 35 out of 40 patients and a clinical cure in 2 out of 40. It was only therapeutically unsuccessful in 3 cases. It is concluded that its microbiological, kinetic and tolerance features make piperacillin suitable for a wide range of therapeutic purposes.
D000150:Acinetobacter / Q000187:drug effects; D000293:Adolescent; D000328:Adult; D000368:Aged; D002006:Brucellosis / Q000188:drug therapy; D002648:Child; D003556:Cystitis / Q000188:drug therapy; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D007710:Klebsiella Infections / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010406:Penicillins / Q000627:therapeutic use*; D010878:Piperacillin; D011511:Proteus / Q000187:drug effects; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects
D010406:Penicillins; D010878:Piperacillin
Piperacillina: ricerca microbiologica e clinica.